GÖRMƏ SİNİRİNİN İŞEMİK XƏSTƏLİKLƏRİNİN MÜALİCƏSİNƏ DAİR

Xülasə

SUMMARY

Aim - to study the effectiveness and methods of use of the drug "Mexidol" in the treatment of patients with
ischemic diseases of the optic nerve.

Material and methods
We studied 45 patients with acute and chronic ischemic neuropathy aged 30 to 63 years, including 35 women, 10
men. Mexidol was prescribed to patients in the form of a solution for intravenous and intramuscular administration
at a dose of 100 and 250 mg / day.
All patients received therapy for two weeks. The effectiveness and tolerability of therapy was evaluated on the
30th day from the start of treatment.

Results
The results show that the use of Mexidol at a dose of 250 mg per day intravenously in 400 ml of sodium
chloride daily for two weeks was more effective, which is confirmed by the VEP and perimetry data.
Before treatment of pattern VEP OD the latency of P2 component within norm, is noted significant decrease in
amplitude (umensheniye amounts of functional fibers of an optic nerve).
In a month of pattern VEP OD the latency of P2 component within norm, is noted decrease in amplitude
of average degree (reduction of amount of functional fibers of an optic nerve in average degree). In dynamics
improvement of indicators of the right eye is noted.
In 3 months of OD the latency of P100 component within norm, is noted insignificant decrease in amplitude
(insignificant reduction of amount of functional fibers of an optic nerve).

Conclusion
According to the results, the drug has antihypoxic, antioxidant, nootropic and membrane protective effects,
which is reflected in the improvement of the studied parameters VEP and perymetry. To achieve the best treatment
results, patients with ischemic optic neuropathy should be prescribed mexidol at a dose of 250 mg per day
intravenously in 400 ml of sodium chloride solution daily for two weeks.